Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share (OACC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: OACC (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 1.84% | Avg. Invested days 35 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 257.94M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 9.95 - 10.85 | Updated Date 06/29/2025 |
52 Weeks Range 9.95 - 10.85 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 256669950 | Price to Sales(TTM) - |
Enterprise Value 256669950 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 19783000 | Shares Floating 18332353 |
Shares Outstanding 19783000 | Shares Floating 18332353 | ||
Percent Insiders - | Percent Institutions 82.19 |
Upturn AI SWOT
Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share
Company Overview
History and Background
Oaktree Acquisition Corp. III Life Sciences was a blank check company (SPAC) formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. It did not have significant operations.
Core Business Areas
Leadership and Structure
Typically led by a management team with experience in private equity and the life sciences industry. The specific structure involves a board of directors and executives focused on identifying and executing an acquisition.
Top Products and Market Share
Key Offerings
Market Dynamics
Industry Overview
The SPAC market experienced booms and busts with increased regulatory scrutiny. The Life Sciences industry is characterized by high growth potential but also high risk and long development cycles.
Positioning
Oaktree Acquisition Corp. III Life Sciences' position was dependent on its ability to find and successfully merge with a suitable target company in the life sciences sector.
Total Addressable Market (TAM)
TAM varies depending on the potential acquisition target. Its positioning was that of a financial vehicle seeking to participate in that market by acquiring an existing business.
Upturn SWOT Analysis
Strengths
Weaknesses
- Lack of operating history
- Dependence on finding a suitable target company
- Regulatory risks associated with SPACs
Opportunities
- Successful merger with a high-growth life sciences company
- Capitalizing on market trends in the life sciences sector
Threats
- Failure to find a suitable target company
- Increased competition from other SPACs
- Market volatility
Competitors and Market Share
Key Competitors
Competitive Landscape
Its competitive landscape consisted of other SPACs seeking acquisition targets in the life sciences industry.
Growth Trajectory and Initiatives
Historical Growth: Growth trajectory is contingent on the acquired company's performance.
Future Projections: Future projections are not applicable, as the company did not make any acquisitions.
Recent Initiatives: Focus on identifying and pursuing potential acquisition targets in the life sciences sector. None happened.
Summary
Oaktree Acquisition Corp. III Life Sciences was a SPAC that never completed an acquisition and had to dissolve. It aimed to merge with a company in the life sciences sector, but did not find a suitable candidate. The company was exposed to SPAC-related risks and competition. As a result, it never achieved significant operating results.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC filings, company press releases, financial news outlets.
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share
Exchange NASDAQ | Headquaters Los Angeles, CA, United States | ||
IPO Launch date 2024-12-16 | CEO & Director Mr. Zaid Pardesi | ||
Sector Financial Services | Industry Shell Companies | Full time employees - | |
Full time employees - | |||
Oaktree Acquisition Corp. III Life Sciences does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to target companies in the biopharmaceutical, medical devices, diagnostics, and specialized healthcare services sectors in North America and Europe. The company was incorporated in 2024 and is based in Los Angeles, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.